|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 26. |
(WO 2007/098130) NOVEL POOLING AND DECONVOLUTION STRATEGY FOR LARGE SCALE SCREENING
|
30.08.2007
|
G06F 19/00
|
PCT/US2007/004313
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
Embodiments of the present invention provide methods, systems, kits, and apparatus for data analysis to detect interactions between atoms, molecules and/or cells. One embodiment of the present invention provides for a novel pooling-deconvolution strategy that can dramatically decrease the effort required to generate large-scale data sets. This 'PI-Deconvolution' strategy employs an N-digit base-X imaginary coding of XN probe proteins (baits or preys) and allows the screening of the baits in X*N pools, with N replicates for each bait. Deconvolution of proteins with their binding partners can be achieved by reading the prey's profile from the X*N experiments. The method can be used to screen XN bait or prey proteins.
|
| |
|
| 27. |
(WO 2007/098114) CLOTTING AND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS
|
30.08.2007
|
A01N 37/18
|
PCT/US2007/004283
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
| |
Disclosed are optimized keratin preparations for use in medical applications. Methods to produce optimized keratin preparations are provided for use in biomedical applications, particularly for the treatment of bleeding, and for the treatment of wounds. Also disclosed are surgical or paramedic aids comprising a substrate with keratin preparations provided thereon, and kits comprising keratin derivatives packaged in sterile form.
|
| |
|
| 28. |
(WO 2007/098113) CCR3 INHIBITION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION
|
30.08.2007
|
A61K 31/445
|
PCT/US2007/004281
|
UNIVERSITY OF KENTUCKY
|
| |
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
|
| |
|
| 29. |
(WO 2007/098111) PREPARATION OF UNIFORM NANOPARTICLES OF ULTRA-HIGH PURITY METAL OXIDES, MIXED METAL OXIDES, METALS, AND METAL ALLOYS
|
30.08.2007
|
B22F 1/00
|
PCT/US2007/004279
|
BRIGHAM YOUNG UNIVERSITY
|
| |
Compositions containing metal nanoparticles, mixed-metal (alloy) nanoparticles, metal oxide nanoparticles and mixed-metal oxide nanoparticles with narrow size distributions and high purities. Methods of preparing metal nanoparticles, mixed-metal nanoparticles, metal oxide nanoparticles and mixed-metal nanoparticles are also provided.
|
| |
|
| 30. |
(WO 2007/098108) BIOADHESIVE FROM DISTILLERS' DRIED GRAINS WITH SOLUBLES (DDGS) AND THE METHODS OF MAKING THOSE
|
30.08.2007
|
A01N 65/00
|
PCT/US2007/004275
|
MICHIGAN STATE UNIVERSITY
|
| |
A bioadhesive composition from distillers' dried grains with solubles (DDGS) is produced by reaction with an aqueous solution of a base, particularly, sodium hydroxide. Optionally, urea is included with the base. The bioadhesive composition is filtered as a solution from the residue of the reaction with the base. The bioadhesive composition s particularly useful as a boxboard glue.
|
| |
|
| 31. |
(WO 2007/098104) ON-BOARD FRACTIONATION SYSTEM AND METHODS TO GENERATE AN ENGINE STARTING FUEL
|
30.08.2007
|
F02B 51/00
|
PCT/US2007/004268
|
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
|
| |
A Fuel Fractionation System (FFS) and associated methods to generate and store a fuel for internal combustion engines is provided. FFS provides a distillation column assembly (31) including a distillation column (33) to distill liquid fuel to form a volatile light fraction secondary fuel. The distillation column (33) includes a vaporization module (61) to vaporize a feed fuel in the distillation column and includes a condensation module (63) to condense heavy fraction components of the vaporized feed fuel. FFS also provides a controller (71) positioned to control the vaporization of feed fuel in the distillation column (33) to thereby control the separation of the feed fuel into light fraction fuel and heavy fraction fuel components, and po...
|
| |
|
| 32. |
(WO 2007/098082) RADIO FREQUENCY IDENTIFICATION DEVICE FOR PLASTIC CONTAINER AND METHOD OF MANUFACTURE OF SAME
|
30.08.2007
|
G06K 19/077
|
PCT/US2007/004242
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
The subject invention pertains to a method and system for identifying goods contained within a container. In an embodiment, a method of manufacturing a plastic container with an embedded RPID tag is provided. In an embodiment, a system includes a plastic container and plastic substrate, with an RFID tag disposed on the substrate. In an embodiment, the substrate can be embedded in a surface of the plastic container. In a further specific embodiment, the substrate can be a label used for in-mold labeling. Such a label can provide the labeling, or markings, for the container. Labeling the container and embedding an RFID tag during the same injection step can save time and costs.
|
| |
|
| 33. |
(WO 2007/098066) POLYMERIC HEART RESTRAINT
|
30.08.2007
|
A61F 2/00
|
PCT/US2007/004216
|
STANFORD UNIVERSITY
|
| |
Described here are polymer compositions, methods, and systems for reinforcing a wall of a heart. The polymer compositions may be adapted to form networks, e.g., cross-linked networks, semi-interpenetrating networks, or interpenetrating networks, and placed within the pericardial space or on one or more pericardial tissues. The mechanical properties of the polymer compositions or networks derived therefrom may then be employed to reinforce a heart wall to prevent dilatation of a chamber of the heart and/or expansion of an infarct, e.g., to treat or prevent congestive or chronic heart failure.
|
| |
|
| 34. |
(WO 2007/098060) METHODS AND AGENTS FOR MODULATING AN IMMUNE RESPONSE
|
30.08.2007
|
A01N 43/44
|
PCT/US2007/004208
|
THE ROCKEFELLER UNIVERSITY
|
| |
This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject.
|
| |
|
| 35. |
(WO 2007/098053) COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS
|
30.08.2007
|
A61F 13/00
|
PCT/US2007/004193
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
| |
Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.
|
| |
|
| 36. |
(WO 2007/098037) SEQUENTIAL REPORTER ENZYME LUMINESCENCE (SRL) METHODS AND COMPOSITIONS FOR PRACTICING THE SAME
|
30.08.2007
|
C12Q 1/66
|
PCT/US2007/004115
|
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
|
| |
Sequential reporter enzyme luminescence (SRL) methods are provided. In the subject methods, the activity of a reporter enzyme is evaluated using a secondary reporter system that employs a product of a reporter enzyme mediated reaction as a luminescent substrate, e.g., luciferase substrate. Also provided are kits and other compositions that find use in practicing the subject methods.
|
| |
|
| 37. |
(WO 2007/098034) MID-IR LASER INSTRUMENT FOR ANALYZING A GASEOUS SAMPLE AND METHOD FOR USING THE SAME
|
30.08.2007
|
H01S 3/10
|
PCT/US2007/004102
|
MIROV, Sergey
|
| |
An optical nose for detecting the presence of molecular contaminants in gaseous samples utilizes a tunable seed laser output in conjunction with a pulsed reference laser output to generate a mid-range IR laser output in the 2 to 20 micrometer range for use as a discriminating light source in a photo-acoustic gas analyzer.
|
| |
|
| 38. |
(WO 2007/098033) FEEDBACK PRODRUG
|
30.08.2007
|
A61K 47/48
|
PCT/US2007/004100
|
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC .
|
| |
Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.
|
| |
|
| 39. |
(WO 2007/098028) PHOTOLUMINESCENT POINT LIGHT SOURCE
|
30.08.2007
|
G12B 21/06
|
PCT/US2007/004089
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
One embodiment of the present invention provides a system that generates a point light source. During operation, the system illuminates a sharp probe using an excitation light, wherein the sharp probe is made of a photoluminescent (PL) material. Illuminating the sharp probe causes a PL emission from the sharp probe. This PL emission generates a point light source at the apex of the sharp probe, wherein the spot size of the point light source is restricted by the radius of curvature of the apex of the sharp probe. Another embodiment of the present invention provides a system that generates a wavelength-tunable point light source. During operation, the system coats a sharp probe with a layer of photoluminescent (PL) material. The system then ...
|
| |
|
| 40. |
(WO 2007/098021) PHOTON-CONVERSION MATERIALS (PCMS) IN POLYMER SOLAR CELLS-ENHANCEMENT EFFICIENCY AND PREVENTION OF DEGRADATION
|
30.08.2007
|
H01L 31/042
|
PCT/US2007/004073
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
A photovoltaic device has a photovoltaic cell and a photon-conversion component. The photon-conversion component has a photon-conversion material in its composition. The photon-conversion material, while the photovoltaic device is in operation, converts photons in a spectral region including a first wavelength to photons in a spectral region including a second wavelength, the second wavelength being longer than the first wavelength. The photons having the second wavelength are at least one of less damaging to the photovoltaic cell than photons having the first wavelength or converted more efficiently to an electrical current than photons having the first wavelength.
|
| |
|
| 41. |
(WO 2007/098011) HIGH FIELD MAGNETIC RESONANCE
|
30.08.2007
|
G01V 3/00
|
PCT/US2007/004040
|
REGENTS OF THE UNIVERSITY OF MINNESOTA
|
| |
This document discloses, among other things, multi-channel magnetic resonance using a TEM coil.
|
| |
|
| 42. |
(WO 2007/098010) IMPROVED LOW MOLECULAR WEIGHT MYC-MAX INHIBITORS
|
30.08.2007
|
A61K 31/427
|
PCT/US2007/004039
|
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
|
| |
Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.
|
| |
|
| 43. |
(WO 2007/098001) COTTON PLANT WITH SEED-SPECIFIC REDUCTION IN GOSSYPOL
|
30.08.2007
|
C12N 15/82
|
PCT/US2007/004023
|
THE TEXAS A & M UNIVERSITY SYSTEM
|
| |
A method is disclosed for reducing the level of gossypol in cottonseed. The method generally includes selectively inducing RNA gene silencing in the seed of a transgenic cotton plant, to interfere with expression of the δ-cadinene synthase gene or the δ-cadinene-8-hydroxylase gene in the seed of the cotton plant without substantially affecting expression of that gene in the foliage, floral parts, and roots of the plant. The transgenic cotton plant comprises at least one of a δ-cadinene synthase gene trigger sequence and/or a δ-cadinene-8- hydroxylase gene trigger sequence operably linked to one or more a seed- specific promoter gene sequences, and the trigger sequence(s) is/are able to induce RNA gene silencing when expressed in cottons...
|
| |
|
| 44. |
(WO 2007/097940) RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE
|
30.08.2007
|
A61K 38/00
|
PCT/US2007/003712
|
TRUSTEES OF BOSTON UNIVERSITY
|
| |
The present invention is directed to the use of RecA inhibitors as antibiotic agents, and provides RecA inhibitors useful in treating infections. Also provided are various compositions and methods associated with RecA inhibition.
|
| |
|
| 45. |
(WO 2007/097922) RECEPTOR-BASED BLOOD DETOXIFICATION SYSTEM
|
30.08.2007
|
A61K 9/00
|
PCT/US2007/003392
|
THE REGENTS OF NORTHWESTERN UNIVERSITY
|
| |
The invention discloses compositions of matter and methods of using such compositions to detoxify blood and blood products. The invention as particular use in the treatment of diabetes, Alzheimer's disease, hemodialysis associated amyloidosis, and cardiovascular complications.
|
| |
|
| 46. |
(WO 2007/097857) MULTIDIMENSIONAL ORGANIZATION OF HETEROMOLECULES BY ROBUST DNA MOTIFS
|
30.08.2007
|
C07H 21/04
|
PCT/US2007/001780
|
NEW YORK UNIVERSITY
|
| |
Two dimensional polynucleic acid arrays are assembled from robust nucleic acid motifs as polygonal units. The polygonal units in an array have edges composed of nucleic acid multi-crossover domains and are joined together by double cohesion of adjacent polygonal units. A subset of polygonal units in the array have a nanoparticle or pendant molecule attached to an end of one edge of each polygonal unit within this subset.
|
| |
|
| 47. |
(WO 2007/097828) METHOD FOR IDENTIFYING AND VALIDATING DOMINANT T HELPER CELL EPITOPES USING AN HLA-DM-ASSISTED CLASS II BINDING ASSAY
|
30.08.2007
|
G01N 33/68
|
PCT/US2007/000180
|
THE JOHNS HOPKINS UNIVERSITY
|
| |
Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-MHC complexes are in many cases inadequate for a number of reasons. Disclosed herein is a reductionistic system incorporating known participants of MHC class II antigen processing in solution to generate peptide pools from antigens, including those for which no immunodominant epitope has yet been identified, that are highly enriched for proteolytic fragments containing their immunodominant epitopes. HLA-DM-mediated editing contributes significantly to immunodominance and is exploited in discovering immunodominant epitopes from novel or previously uncharacterized antigens, part...
|
| |
|
| 48. |
(WO 2007/097820) VIRAL GENE PRODUCTS AND METHODS FOR VACCINATION TO PREVENT VIRAL ASSOCIATED DISEASES
|
30.08.2007
|
A61K 39/395
|
PCT/US2006/061062
|
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
|
| |
Methods of vaccination to prevent virus-associated diseases, which methods generally result in an increase of virus-specific memory T cells that provide or restore host immunity and result in control of the viral-associated disease process. Polypeptides and DNA sequences for achieving these results are also described. In some embodiments, the virus is Epstein- Barr virus.
|
| |
|
| 49. |
(WO 2007/097789) ATTENUATED FRANCISELLA AND METHODS OF USE
|
30.08.2007
|
A01N 63/00
|
PCT/US2006/043059
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
| |
Francisella tularensis is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life- threatening disease. The present disclosure provides attenuated Francisella mutants that include functional deletions in one or more of the dsbB, FTT0742, pdpB,fumA, and carB genes. Also provided are immunogenic compositions that include the attenuated bacteria. Methods are provided for treatment using the attenuated Francisella mutants.
|
| |
|
| 50. |
(WO 2007/097751) METHODS FOR REDUCING GLUCOSE INTOLERANCE BY INHIBITING CHOP
|
30.08.2007
|
C12N 15/11
|
PCT/US2006/006345
|
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
|
| |
Provided herein are methods for preventing and treating glucose intolerance related diseases in a subject or in cells thereof. A method may comprise administering to a subject or cells thereof an agent that inhibits the protein level or activity of a CHOP protein. A method may also comprise contacting pancreatic islet cells with such an agent and administering the cells to a subject in need thereof.
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
